StockNews.com Begins Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

Investment analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ:TCON opened at $0.11 on Thursday. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75. The company has a market capitalization of $358,050.00, a PE ratio of 0.16 and a beta of 1.35. The business has a fifty day moving average price of $0.19 and a two-hundred day moving average price of $1.89.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The company had revenue of $0.06 million for the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.